Additionally, the 36-month beta value for MYNZ is 0.21. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for MYNZ is 1.86M and currently, short sellers hold a 4.73% ratio of that float. The average trading volume of MYNZ on December 23, 2024 was 108.91K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MYNZ) stock’s latest price update
The stock price of Mainz Biomed N.V (NASDAQ: MYNZ) has surged by 40.04 when compared to previous closing price of 4.77, but the company has seen a 24.63% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-19 that BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V.
MYNZ’s Market Performance
MYNZ’s stock has risen by 24.63% in the past week, with a monthly drop of -25.45% and a quarterly drop of -16.58%. The volatility ratio for the week is 22.81% while the volatility levels for the last 30 days are 19.47% for Mainz Biomed N.V The simple moving average for the past 20 days is -0.18% for MYNZ’s stock, with a -66.17% simple moving average for the past 200 days.
Analysts’ Opinion of MYNZ
H.C. Wainwright gave a rating of “Buy” to MYNZ, setting the target price at $25 in the report published on June 21st of the previous year.
MYNZ Trading at -25.08% from the 50-Day Moving Average
After a stumble in the market that brought MYNZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -87.54% of loss for the given period.
Volatility was left at 19.47%, however, over the last 30 days, the volatility rate increased by 22.81%, as shares sank -21.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -48.42% lower at present.
During the last 5 trading sessions, MYNZ rose by +24.63%, which changed the moving average for the period of 200-days by -82.27% in comparison to the 20-day moving average, which settled at $6.69. In addition, Mainz Biomed N.V saw -85.60% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MYNZ
Current profitability levels for the company are sitting at:
- -31.23 for the present operating margin
- 0.57 for the gross margin
The net margin for Mainz Biomed N.V stands at -30.58. The total capital return value is set at -3.27.
Based on Mainz Biomed N.V (MYNZ), the company’s capital structure generated 0.65 points at debt to capital in total, while cash flow to debt ratio is standing at -2.73.
Currently, EBITDA for the company is -25.01 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 21.27. The receivables turnover for the company is 1.82for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.97.
Conclusion
In conclusion, Mainz Biomed N.V (MYNZ) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
